0001209191-21-022557.txt : 20210323
0001209191-21-022557.hdr.sgml : 20210323
20210323162312
ACCESSION NUMBER: 0001209191-21-022557
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210319
FILED AS OF DATE: 20210323
DATE AS OF CHANGE: 20210323
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arjona Ferreira Juan Camilo
CENTRAL INDEX KEY: 0001714080
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 21765048
MAIL ADDRESS:
STREET 1: C/O MYOVANT SCIENCES INC.
STREET 2: 2000 SIERRA POINT PARKWAY, 9TH FLOOR
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER NAME:
FORMER CONFORMED NAME: Ferreira Juan Camilo Arjona
DATE OF NAME CHANGE: 20170807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Myovant Sciences Ltd.
CENTRAL INDEX KEY: 0001679082
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: CA
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
BUSINESS PHONE: 44 207-400-3351
MAIL ADDRESS:
STREET 1: SUITE 1, 3RD FLOOR
STREET 2: 11-12 ST. JAMES SQUARE
CITY: LONDON
STATE: X0
ZIP: SW1Y 4LB
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-19
0
0001679082
Myovant Sciences Ltd.
MYOV
0001714080
Arjona Ferreira Juan Camilo
C/O MYOVANT SCIENCES INC.
2000 SIERRA POINT PARKWAY, 9TH FLOOR
BRISBANE
CA
94005
0
1
0
0
Chief Medical Officer
Common Shares
2021-03-19
4
M
0
7000
7.78
A
141535
D
Common Shares
2021-03-19
4
S
0
7000
24.17
D
134535
D
Stock Option (Right to Buy)
7.78
2021-03-19
4
M
0
7000
0.00
D
2028-04-15
Common Shares
7000
73550
D
Shares sold pursuant to a 10b5-1 trading plan.
The shares were sold at prices ranging from $24.01 to $24.42. The reporting person will provde upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
/s/ Matthew Lang, Attorney-in-fact
2021-03-23